Correlation Between Bristol Myers and CG Oncology,
Can any of the company-specific risk be diversified away by investing in both Bristol Myers and CG Oncology, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and CG Oncology, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bristol Myers Squibb and CG Oncology, Common, you can compare the effects of market volatilities on Bristol Myers and CG Oncology, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of CG Oncology,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and CG Oncology,.
Diversification Opportunities for Bristol Myers and CG Oncology,
-0.45 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Bristol and CGON is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and CG Oncology, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CG Oncology, Common and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with CG Oncology,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CG Oncology, Common has no effect on the direction of Bristol Myers i.e., Bristol Myers and CG Oncology, go up and down completely randomly.
Pair Corralation between Bristol Myers and CG Oncology,
Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.93 times more return on investment than CG Oncology,. However, Bristol Myers Squibb is 1.08 times less risky than CG Oncology,. It trades about 0.12 of its potential returns per unit of risk. CG Oncology, Common is currently generating about -0.02 per unit of risk. If you would invest 5,577 in Bristol Myers Squibb on September 1, 2024 and sell it today you would earn a total of 345.00 from holding Bristol Myers Squibb or generate 6.19% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 95.45% |
| Values | Daily Returns |
Bristol Myers Squibb vs. CG Oncology, Common
Performance |
| Timeline |
| Bristol Myers Squibb |
| CG Oncology, Common |
Bristol Myers and CG Oncology, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Bristol Myers and CG Oncology,
The main advantage of trading using opposite Bristol Myers and CG Oncology, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, CG Oncology, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will offset losses from the drop in CG Oncology,'s long position.| Bristol Myers vs. Crinetics Pharmaceuticals | Bristol Myers vs. Enanta Pharmaceuticals | Bristol Myers vs. Amicus Therapeutics | Bristol Myers vs. Connect Biopharma Holdings |
| CG Oncology, vs. Patterson UTI Energy | CG Oncology, vs. Cheniere Energy Partners | CG Oncology, vs. Drilling Tools International | CG Oncology, vs. NRG Energy |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |